Routine annual meeting filing with no earnings or operational news. The equity plan approval enables future equity grants but does not trigger immediate dilution. Monitor for subsequent option grants or S-8 filings that would indicate actual share issuance.
Price Chart
Executive Summary
Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the amended and restated 2021 Equity Incentive Plan (adding 1,850,000 new shares for a total reserve of 5,190,000 shares) and re-elected three Class III directors. The filing is a routine governance update with no material financial data or operational changes.
Key Facts
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan with 11,911,879 votes for, 3,997,050 against, and 351,042 abstentions.
- The plan reserves 5,190,000 shares total, including 1,850,000 newly requested shares.
- Three Class III directors (Steven Kornfeld, Scott Brun, Paul A. Wagner) were re-elected.
- KPMG LLP was ratified as independent auditor for FY2026 with 17,722,893 votes for.
- Advisory vote on executive compensation passed with 12,143,153 votes for.
- No officer departures, no financial results, and no guidance were reported.
Financial Impact
No financial figures reported; the equity plan adds 1,850,000 new shares to the reserve, representing potential future dilution of approximately 9% of the 20,478,817 shares outstanding.
Risk Factors
- Potential future dilution from equity awards under the approved plan.
- No cross-filing context provided; no other corporate events to assess.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-253436 |
| Document: d110060d8k.htm | 0001193125-26-253436 |
| Document: 0001193125-26-253436-index-headers.html | 0001193125-26-253436 |
| Document: 0001193125-26-253436-index.html | 0001193125-26-253436 |
| Document: 0001193125-26-253436.txt | 0001193125-26-253436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | EFFECT | $76.99 awaiting T+1 | awaiting T+1 | — | — |
Sep 2, 2026 4w ago | EFFECT | $76.99 awaiting T+1 | awaiting T+1 | — | — |
Aug 27, 2026 5w ago | 25-NSE | $76.99 $76.99 | · 0.00% | ▼ −0.23% | — |
Jul 27, 2026 9w ago | 8-K | $76.50 $76.65 | ▲ +0.20% | ▼ −0.04% | — |
Jun 11, 2026 16w ago | EFFECT | $17.40 $17.56 | ▼ −0.92% | ▼ −0.38% | — |
Jun 6, 2026 16w ago | S-3/A | $15.67 $17.00 | ▼ −8.49% | ▼ −8.78% | — |
Jun 2, 2026 17w ago | S-3 | $17.00 $16.69 | ▲ +1.82% | ▲ +2.22% | — |
Jun 2, 2026 17w ago | 8-K | $17.00 $16.69 | ▼ −1.82% | ▼ −2.23% | — |
May 14, 2026 20w ago | 8-K | $23.11 $20.97 | ▼ −9.26% | ▼ −9.20% | — |
Apr 9, 2026 25w ago | 8-K | $33.90 $35.09 | ▲ +3.51% | ▲ +3.57% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access